Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Leap Therapeutics Inc LPTX

Healthcare Biotechnology
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic... see more

Recent & Breaking News (NDAQ:LPTX)

Leap Therapeutics Reports Third Quarter 2024 Financial Results

PR Newswire 10 days ago

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

PR Newswire September 30, 2024

Leap Therapeutics Reports Second Quarter 2024 Financial Results

PR Newswire August 12, 2024

Leap Therapeutics Reports First Quarter 2024 Financial Results

PR Newswire May 13, 2024

Leap Therapeutics Announces $40 Million Private Placement

PR Newswire April 11, 2024

Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

PR Newswire March 18, 2024

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

PR Newswire January 16, 2024

Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire January 3, 2024

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

PR Newswire January 2, 2024

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium

PR Newswire December 11, 2023

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

PR Newswire November 21, 2023

Leap Therapeutics Reports Third Quarter 2023 Financial Results

PR Newswire November 13, 2023

Leap Therapeutics to Participate at Upcoming Investor Conferences

PR Newswire September 5, 2023

Leap Therapeutics Reports Second Quarter 2023 Financial Results

PR Newswire August 14, 2023

Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

PR Newswire July 12, 2023

Leap Therapeutics Announces Reverse Stock Split

PR Newswire June 20, 2023

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

PR Newswire May 25, 2023

Leap Therapeutics Reports First Quarter 2023 Financial Results

PR Newswire May 15, 2023

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

PR Newswire April 26, 2023

Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

PR Newswire April 12, 2023